Investigators at the University of Buenos Aires, in Argentina, found that patients taking second-generation antipsychotics who experienced a high level or an intermediate level of metabolic changes had an almost threefold increased risk of experiencing a cardiovascular event ― especially stroke ― compared to their counterparts taking medications that were associated with a lower risk for metabolic changes.
The authors state that the higher risk for major cardiovascular events among those taking intermediate- or high-risk agents "appears to be mostly driven by the enhanced risk of stroke among our population, something that might be due to the high prevalence of patients with dementia or related to potential direct or indirect effects of antipsychotics."